Elexacaftor + tezacaftor + ivacaftor

  • 1 lab in 1 country
  • Funders: Canada Research Chairs and 3 more
  • Human trial1

Outcomes

1

GrimAge2

downin humans1

1 study
  1. Elexacaftor + tezacaftor + ivacaftor decreases GrimAge2 in humans (from 1.92 years to -1.70 years (p=0.008)).

    “DNAmGrimAge2 age acceleration decreased after ETI treatment, from a median of 1.92 years before treatment to -1.70 years after 1 year (p=0.008).”

    Human trial1 yearn = 8

    Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis

    bioRxiv18 Sep 2026Preprint

More on GrimAge2

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 01 in 12 months